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Abstract
Human herpesvirus type 6B (HHV-6B) is a strong inducer of IFN-alpha and has the capacity to promote Th1 responses and
block Th2 responses in vitro. In this study we addressed whether inactivated HHV-6B can also induce IFN lambda responses
and to what extent interferons alpha and lambda affect Th1/Th2 polarization. We show that inactivated HHV-6B induced
IFN-lambda1 (IL-29) but not IFN-lambda2 (IL-28A) responses in plasmacytoid DC and that this induction was mediated
through TLR9. We have previously shown that HHV-6B promotes Th1 responses and blocks Th2 responses in both humans
and mice. We now show that neutralization of IFN-alpha but not IFN-lambda1 blocked the HHV-6B-induced enhancement
of Th1 responses in MLR, but did not affect the HHV-6-induced dampening of Th2 responses. Similarly, blockage of TLR9
counteracted HHV-6Bs effects on the Th1/Th2 balance. In addition, IFN-alpha but not IFN-lambda1 promoted IFN-gamma
production and blocked IL-5 and IL-13 production in purified CD4+ T-cells. The lack of effect of IFN-lambda1 correlated with
the absence of the IFN-lambda receptor IL-28Ralfa chain on the cell surface of both resting and activated CD4+ T-cells. We
conclude that inactivated HHV-6B is a strong inducer of IFN-lambda1 in plasmacytoid DC and that this induction is TLR9-
dependent. However, human CD4+ T-cells do not express the IFN-lambda receptor and are refractory to IFN-lambda1
treatment. The HHV-6B-induced alterations in the Th1/Th2 balance are instead mediated mainly through TLR9 and IFN-
alpha.
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Introduction
The recently discovered type III IFNs share many of the anti-
viral properties of type I IFNs. The family consists of three
members, IFN-lambda1 (IL-29), IFN-lambda2 (IL-28A), and IFN-
lambda3 (IL-28B) and are commonly referred to as the IFN-
lambda family [1,2]. All three IFN-lambdas utilize a common
distinct receptor, the IFN-lambdaR, which is composed of the IL-
10R2 chain and the unique IL-28Ralpha chain [2,3]. The IFN-
lambdaR is expressed at high densities on epithelial cells [3] but
IL-28Ralpha transcripts might also be found in other cells
including blood lymphocytes [2]. Binding of IFN-lambda to its
receptor induces a signaling response similar to that obtained by
type I IFNs [1], even though the intensity of the IFN-lambda
response is generally weaker [1,4]. The anti-viral effects obtained
by IFN-lambda protects against some but not all viral infections,
and preferentially those that occur at mucosal surfaces [5,6].
Type I IFNs are pleiotropic and have, in addition to their anti-
viral properties, also T-cell immune-modulatory functions, e.g. in
driving Th1 responses. IFN-alpha not only promotes IFN-gamma
production by CD4+ and CD8+ T-cells [7,8] but can also re-direct
an already established Th2 response into a more Th1-like response
[9]. IFN-lambda share some of the immune-modulatory functions
of IFN-alpha. Signaling through the IFN-lambdaR induces the
phosphorylation of both STAT 1 and STAT 4 [1,4], i.e.
transcription factors involved in the development of IFN-
gamma/Th1 responses [7,10]. The main T-cell immune-modu-
latory function of IFN-lambda1 that has been reported is in
dampening Th2 responses, in particular IL-13 [11–13]. It is
however not conclusively proven that IFN-lambda has direct
effects on CD4+ T-cell polarization rather than operating through
accessory cells such as dendritic cells and monocytes [14].
Human herpesvirus type 6B (HHV-6B) is the aetiological cause
of exanthema subitum, a benign disease in young children charac-
terized by high fever for 3–5 days. The virus is a strong inducer of
type I IFN responses [15] and exposure to this virus alters the
Th1/Th2 balance both in vitro and in vivo [15,16]. Whether HHV-
6B is also capable of inducing IFN-lambda responses is not known,
and neither is the underlying mechanism for the Th1-promoting
and Th2-dampening effects on CD4+ T-cell responses.
In this study we investigated whether inactivated HHV-6B
could induce the production of IFN-lambda by cord plasmacytoid
dendritic cells (pDC), and to what extent this production
contributed to the documented shift in the Th1/Th2 balance.
We show that inactivated HHV-6B induces the production of
IFN-lambda1 by cord pDC in a TLR9-dependent fashion. IFN-
lambda however had no direct effect on human cord T-cell
polarization, which correlates with the lack of expression of the IL-
28Ralpha on human CD4+ T-cells. We conclude that IFN-
lambda1 has no direct effects on the Th1/Th2 differentiation of
human CD4+ T-cells.
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Inactivated HHV-6B induces IFN-alpha and IFN-lambda1
responses in cord pDC via TLR9
We have previously shown that inactivated HHV-6B induces
a strong IFN-alpha response in cord pDC, which we confirm in
Fig. 1A. In addition, we show that inactivated HHV-6B also
induces high levels of IFN-lambda1 from pDC (Fig. 1B), but no or
little IFN-lambda2 (Fig. 1C). The lack of induction of IFN-
lambda2 was not dependent on the kinetics, at these low levels
remained constant over 72 h (Fig. 1D). It should be noted that the
sensitivity of the ELISAs varied from 10 pg/ml for IFN-alpha,
60 pg/ml for IFN-lambda1 and 100 pg/ml for IFN-lambda2.
This means that we have not been able to detect potential low
IFN-lambda2 responses. The HHV-6B-induced production of
both IFN-alpha and IFN-lambda1 was dependent on TLR9 as it
was completely abolished in the presence of a TLR9-specific
inhibitor, G-ODN (Fig. 1A–B).
Neutralization of IFN-alpha but not IFN-lambda1 blocks
the HHV-6B-induced promotion of Th1 responses in cord
mixed lymphocyte reactions without affecting the HHV-
6-induced dampening of Th2 responses
We have previously shown that HHV-6B exposure promotes
Th1 development and blocks Th2 development both in vitro and in
vivo in humans and in mice [15,16]. To assess whether IFN-alpha
or IFN-lambda1 is implicated in the HHV-6B-induced Th1/Th2
shift in vitro, we performed MLR of cord pDC and CD4+ T-cells in
the presence or absence of HHV-6B and either a specific inhibitor
of TLR9 (G-ODN) or neutralizing antibodies to IFN-alpha or
IFN-lambda1. In titration experiments, we found that at 10 ug/
ml, both these antibodies neutralized 5000 pg/ml of recombinant
IFN-alpha and IFN-lambda1, respectively (not shown). As shown
before [15], the CD4+ T-cell production of IFN-gamma was
increased while the production of IL-5 and IL-13 was decreased in
MLR cultures exposed to HHV-6B (Fig. 2A–C). Neutralizing
antibodies to IFN-alpha blocked the HHV-6B-induced IFN-
gamma responses while neutralizing antibodies to IFN-lambda1
did not have this effect (Fig. 2A). Addition of G-ODN, a specific
blocker of TLR9 signaling, blocked the HHV-6B-induced increase
in IFN-gamma production and also the HHV-6-induced damp-
ening of IL-13 responses in these cultures (Fig. 3). Neutralization of
IFN-alpha or IFN-lambda1 did however not impact on the HHV-
6B-induced dampening of IL-5 and IL-13 responses (Fig. 2B–C).
IFN-alpha but not IFN-lambda1 promotes IFN-gamma
responses and blocks IL-5 and IL-13 responses in
activated cord CD4+ T-cells
To assess whether IFN-lambda1 shares the CD4+ T-cell
immune-modulatory functions of IFN-alpha, we added recombi-
nant human IFN-alpha and IFN-lambda1 to cultures of anti-CD3-
stimulated cord CD4+ T-cells and measured their production of
IFN-gamma, IL-5 and IL-13. To ascertain that the recombinant
cytokines used were biologically functional we first assessed their
ability to induce MxA transcription in purified pDC and found
that four hour incubation with IFN-alpha or IFN-lambda1
enhanced the MxA transcription 50-fold and 10-fold, respectively.
Since anti-CD3 activation alone did not give rise to any
measurable IL-13 responses (not shown), we added soluble anti-
CD28 to these cultures. As expected, IFN-alpha had profound
effects on the cytokine production profiles and promoted both
IFN-gamma and IL-10 responses and blocked IL-5 and IL-13
Figure 1. HHV-6B induces the production of IFN-alpha, IFN-
lambda1 but not IFN-lambda2 in pDC in a TLR9-dependent
fashion. Purified cord pDC were exposed to inactivated HHV-6B in the
presence or absence of G-ODN, a TLR9-specific inhibitor. The levels of
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did not affect the production of any of these cytokines (Fig. 4).
IL28R is not expressed on CD4+ T-cells
IFN-lambda1, IFN-lambda2 and IFN-lambda3 act by binding
to the IFN-lambdaR. We examined the expression of the IFN-
lambdaR-specific IL-28Ralpha chain on pDC (Fig. 5A), resting
CD4+ cells (Fig. 5B) and on CD4+ cells that had been activated for
24 h with anti-CD3 (Fig. 5C) or cultured for 24 h in the presence
of IFN-alpha (Fig. 5D). We found that neither resting nor activated
CD4+ T-cells expressed any detectable levels of IL-28Ralpha
whereas low levels could be detected on pDC.
Discussion
In this study we show that inactivated HHV-6B is a potent
inducer of IFN-lambda1 but not IFN-lambda2 in pDC through
a TLR9-dependent signaling pathway. In addition we show that
IFN-lambda1 does not share the ability if IFN-alpha to directly
alter the function of T-cells. Firstly, T-cells do not express IL-
28Ralpha, i.e. the IFN-lambdaR. Secondly, addition of recombi-
nant IFN-lambda to activated CD4+ T-cells does not change their
Th1/Th2 cytokine profile. Thirdly, neutralization of IFN-lamb-
da1 does not affect virus-induced alterations in the Th1/Th2
balance.
Inactivated HHV-6B was a strong inducer of IFN-lambda1 but
not IFN-lambda2 in cord pDC. Even though IFN-lambda1 genes
are considered to be early response genes whereas IFN-lambda2 is
expressed with delayed kinetics [14], there were no apparent IFN-
lambda2 responses even at 72 h post activation. IFN-lambda2
depends on the inducible IRF7 pathway whereas IFN-lambda1 is
also regulated by the constitutively expressed IRF3 [17]. Since
IRF7 is constitutively expressed in pDC [18], our data clearly
show that pDC produce higher amounts of IFN-lambda1
compared to IFN-lambda2 in response to HHV-6B exposure.
We have previously shown that inactivated HHV-6B can induce
high levels of IFN-alpha by cord pDC [15] and the data from this
study show that both the IFN-alpha and the IFN-lambda1
responses induced by HHV-6B are mediated through TLR9.
This is in accordance with many other herpesviruses such as
varicella zoster virus, HSV and EBV, which all induce type I IFN
responses in pDC through the TLR9 pathway [19–21].
We confirm previous studies showing that IFN-alpha has the
capacity to alter the overall Th1/Th2 balance. That IFN-alpha
has T-cell immune-modulatory functions is well established [7–9]
and reflects the almost universal expression of the IFN-alpha/beta
receptor on nucleated cells. However, when we neutralized IFN-
alpha in HHV-6B-exposed mixed lymphocyte reactions we only
managed to influence the Th1 responses. Thus, addition of
neutralizing antibodies to IFN-alpha blocked the virus-induced
enhancement in IFN-gamma production without affecting the
virus-induced reduction in Th2 cytokines. In contrast, addition of
recombinant IFN-alpha to activated cord CD4+ T-cells affected
both the Th1 and the Th2 responses. In this setting, IFN-alpha
enhanced the production of IFN-gamma and reduced the
production of IL-5 and IL-13. This implies that IFN-alpha indeed
has the capacity to influence both Th1 and Th2 responses. The
IFN-alpha (A; n=20), IFN-lambda1 (B; n=15) and IFN-lambda2 (C; n=5)
were analyzed in 24h culture supernatants. Data are expressed as mean
+ SEM. ** = p,0.01, *** = p,0.001 using ANOVA with Bonferroni’s
multiple comparison test. The levels of IFN-lambda1 and IFN-lambda2
were also assessed over a 72 h time-period (D; n=3).
doi:10.1371/journal.pone.0038683.g001
Figure 2. Neutralization of IFN-alpha but not IFN-lambda1
blocks the HHV-6B-induced promotion of IFN-gamma re-
sponses in cord mixed lymphocyte reactions. Cord blood pDC
were incubated with allogeneic cord-blood CD4+ T-cells in the presence
or absence of inactivated HHV-6B and neutralizing antibodies to IFN-
alpha or IFN-lambda1. Supernatants were collected after 48 h and
analyzed for IFN-gamma (A), IL-5 (B) and IL-13 (C) content. Data are
expressed as medians and the 25% and 75% percentile (the boxes) with
the minimum and maximum responses for n=9. * = p,0.05 using
ANOVA with Bonferronis multiple comparison test.
doi:10.1371/journal.pone.0038683.g002
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the HHV-6B-exposed cord MLR could imply that other factors
than IFN-alpha also has a Th2-dampening effect. In relation to
this, we recently showed that enveloped viruses (in this case
coronavirus, CMV, HSV-1, influenza virus and morbillivirus), but
not naked virus, blocked IL-13 responses in vitro, and that this
inhibition occurred independently of IFN-alpha responses [22].
This would argue for an IFN-alpha-independent modulation of
IL-13 responses by virus such as HHV-6B.
IFN-lambda1 is reported to be especially efficient in dampening
Th2 responses, in particular IL-13 [11–13]. In our hands, IFN-
lambda1 had no such effect. When we added recombinant IFN-
lambda1 to activated cord CD4+ T-cells, we could not document
any effect on either Th1 (IFN-gamma) or Th2 (IL-5 and IL-13)
responses. In addition, neutralization of IFN-lambda1 in HHV-
Figure 3. HHV-6B affects the IFN-gamma and IL-13 responses
in cord mixed lymphocyte reactions via TLR9 signaling. Cord
blood pDC were incubated with allogeneic cord-blood CD4+ T-cells and
inactivated HHV-6B in the presence or absence of G-ODN. Supernatants
were collected after 48 h and analyzed for IFN-gamma (A), IL-5 (B) and
IL-13 (C) content. Data are expressed as medians and the 25% and 75%
percentile (the boxes) with the minimum and maximum responses for
n=5. * = p,0.05 using student’s t-test.
doi:10.1371/journal.pone.0038683.g003
Figure 4. IFN-alpha but not IFN-lambda1 promote Th1
responses and block Th2 responses in activated cord CD4+ T-
cells. Cord blood CD4+ T-cells were activated with anti-CD3 (A–B) or
anti-CD3 and anti-CD28 (C) in the presence or absence of recombinant
human IFN-alpha or IFN-lambda1. Supernatants were collected after
48 h and analyzed for IFN-gamma (A), IL-5 (B) and IL-13 (C) content.
Data are expressed as medians and the 25% and 75% percentile (the
boxes) with the minimum and maximum responses for n=5. * =
p,0.05 using ANOVA with Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0038683.g004
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levels of either Th1 or Th2 cytokines, including IL-13. We
therefore decided to check for the expression of the IFN-lambda
receptor on CD4+ T-cells. Resting CD4+ T-cells did not show any
expression of the IL-28Ralpha chain, nor did CD4+ T-cells that
had been activated with anti-CD3 or exposed to IFN-alpha.
Previous studies have identified IL-28Ralpha transcripts in human
T-cells [13,23] but our data clearly show that there is no IL-
28Ralpha protein expression on the cell surface on neither resting
nor activated CD4+ cells. We thus conclude that IFN-lambda1
does not have direct effects on CD4+ T-cells due to the lack-of-
expression of the cognate cytokine receptor. This is in line with
a recent report by Arasteh et al [24] showing that IFN-lambda2
has no effect on CD25 expression or proliferation of cord CD4+
T-cells. There is however one report showing a direct effect of
IFN-lambda1 on purified human CD4+ T-cells [13]. In this study
it was shown that IFN-lambda not only suppressed GATA-3-
induced Th2 responses but also indirectly enhanced IFN-gamma
responses [13]. However, the authors used negative selection for
the CD4+ purification. Given that the purified cells used were not
completely pure (.95%) indicates that there might have been
some accessory cells left among the CD4+ T-cells [13]. If so, the
effect of IFN-lambda1 could well be mediated indirectly via some
other cell subset.
Monocyte-derived macrophages not monocytes or monocyte-
derived DC express the functional IFN-lambdaR [25]. The
transcript for the IL-28Ralpha has also been found in pDC [26]
and we now show that pDC express low levels of IL28Ralpha on
the cell surface. This indicates to us that IFN-lambda acts
preferentially on certain subsets of antigen-presenting cells and
that the observed effects of IFN-lambda on CD4+ T-cell
differentiation [11–13] are indirect. The most plausible mode of
action of IFN-lambda is through its interaction with myeloid cells
[27]. This assumption is substantiated by in vitro studies showing
that IFN-lambda blocks IL-13 responses and promotes IFN-
gamma responses through its effects on dendritic cells [11,12].
Furthermore, IFN-lambda promotes Th1 responses and blocks
Th2 and Th17 responses in vivo in mice through its modulation of
the IL-12 production by lung myeloid dendritic cells [28]. The
Th2 dampening and Th1 promoting effects could be adoptively
transferred by IL-28A-treated CD11c
+ cells [28].
We have recently shown that infection with HHV-6B before
18 months-of-age is associated with a significantly reduced in-
cidence of allergic sensitization (OR: 0.08, 95% CI: 0.009–0.68)
[15] suggesting that HHV-6B infection might protect children
from allergy. Experimentally, we strengthened this hypothesis by
showing that HHV-6B exposure blocks Th2 responses and allergy
development in a mouse model of allergic disease [16]. In vitro we
showed that HHV-6B can promote Th1 responses (IFN-gamma)
and reduce Th2 responses (IL-5 and IL-13) [15]. The results from
the present study indicate that these effects are mediated in part
through IFN-alpha. We initially hypothesized that IFN-lambda is
implicated in dampening the Th2 responses [11–13], but this was
not the case in our in vitro system. However, IFN-lambda might
well play a role in reducing Th2 responses in vivo, as shown by
Koltsida et al [28].
In summary, we show that inactivated HHV-6B induces IFN-
lambda1 responses in pDC through TLR9. The secreted IFN-
lambda1 does however not affect CD4+ T-cells directly as human




HHV-6B strain Z29 (available from the HHV-6 foundation
repository, www.hhv-6foundation.org/research/repository/
repository-reagents-available) was kindly donated by Dr Helena
Dahl, SMI, Stockholm. The virus was grown in MOLT-3 cells
(available at ATCC: CRL 1552) in Iscoves complete medium
(Iscoves medium with 10% FBS (Biological Industries, Kibbutz
Beit Haemek, Israel), 3 ug ml
21 L-glutamine (Gibco, UK), 0.1 mg
ml
21 gentamycin sulphate (Essex La ¨kemedel AB, Stockholm,
Sweden)) containing 5 ug/ml cortisone (Solucortef, UpJohn). After
2–3 weeks, the suspensions were centrifuged at 1500 rpm. The
Figure 5. CD4+ T-cells do not express IL-28Ralpha. Resting or
activated cord blood mononuclear cells were analyzed for IL-28Ralpha
expression using FACS. IL-28Ralpha expression (histograms) on pDC (A)
or CD4+ T-cells obtained directly upon isolation (B) or after 24 h
incubation with anti-CD3 (C) or recombinant human IFN-alpha (D).
Filled red areas represent isotype-PE control and blue lines represent IL-
28Ralpha-PE.
doi:10.1371/journal.pone.0038683.g005
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100,0006g. The viruses were resuspended in Iscoves complete
medium. Viral content was determined by quantitative PCR. The
virus was inactivated at 2500 rad prior to use.
Activation of pDC
Fresh cord blood pDC were isolated from cord blood mono-
nuclear cells using the pDC isolation kit from Miltenyi Biotec
(Auburn, CA). PDC were dispersed in 24 well plates (10
6 cells/
well) in the presence or absence of virus (70 genome copies/pDC)
in 1 ml Iscoves complete medium. In some experiments, a TLR9
antagonist (G-ODN, 15 uM, InVitrogen) [29] was added.
Supernatants were collected after 24 h, 48 h and 72 h and frozen
at 270uC until assayed for cytokine content.
Activation of CD4+ cells
Cord CD4+ T-cells were isolated from pDC-depleted CBMC
using the Dynal CD4
+ Isolation Kit according to manufacturer’s
instructions (Invitrogen AB, Stockholm, Sweden) yielding .95%
pure CD4+ T-cells. The cells were cultured in 96 well flat-bottom
Nunc tissue culture plates (10
5 cells/well) pre-coated with 3 ug/ml
anti-human CD3 (3 ug/ml, OKT-3, Ortho-McNeil Pharmaceu-
tical, Raritan, NJ) in Iscoves complete medium in the presence or
absence of anti-human CD28 (1 ug/ml, BD), recombinant human
IFN-alpha (10 ug/ml; PBL interferon source) or IFN-lambda1
(10 ug/ml; Peprotech). Supernatants were collected after 48h and
analyzed for cytokine content (see below).
Mixed lymphocyte reaction
Cord CD4+ T-cells (10
5) were cultured with allogeneic cord
pDC (2610
4) in 96 well flat-bottom Nunc tissue culture plates in
Iscoves complete medium together with irradiated HHV-6 (70
genome copies/pDC), in the presence or absence of G-ODN
(15 uM) or neutralizing antibodies to human IFN-alpha (10 ug/
ml; PBL interferon source) or IFN-lambda1 (10 ug/ml; R&D,
catnr: MAB15981). Supernatants were collected after 48 h and
analyzed for cytokine content (see below).
Cytokine analysis
IFN-alpha content was assessed using an ELISA kit from PBL
Biomedical Laboratories. IFN-lambda1, IFN-lambda2, and IL-13
levels were determined using specific Duoset ELISAs (R&D). IFN-
gamma and IL-5 contents were determined using the Human
Th1/Th2 Cytokine Cytometric Bead Array Kit (BD Biosciences
Pharmingen, San Diego, CA) using a FacsCanto2 flow cytometer
and the data were analysed using the FCAP array Software (BD
Biosciences Pharmingen).
FACS analysis
Cord cells were analyzed directly upon isolation or after 24 h
incubation with IFN-alpha (5 ug/ml) or solid-phase anti-CD3
(3 ug/ml). For the staining, 10
6 cells were treated for 20 min with
Fc-block (BD Pharmingen) and then incubated with anti-IL28R-
PE (R&D, catalogue number FAB5260P) or a PE-labelled isotype
control (mouse IgG) together with anti-CD4-Pacific blue (BioLe-
gend) for 30 min. Stained cells were analyzed in an iCyt Eclipse
(Sony) and the data generated were processed with FlowJo version
7.6.5.
Relative quantification of MxA mRNA
Total RNA was isolated from pDC that had been cultured for
6 h with recombinant IFN-alpha or IFN-lambda1, using the
RNeasy kit from Qiagen according to manufacturer’s instructions.
Total RNA was used for cDNA synthesis using 0.5 mg/ml random
hexamer and 0.01 mM dNTP in a total volume of 12 ml. This was
followed by heating to 65uC for 5 minutes, a quick chill on ice and
brief centrifugation. 20–40 U/ml RNase inhibitor, 0.2 mM DTT,
1x First-Strand buffer and 200 U/ml SuperscriptRT was then
added and incubated at 37uC for 50 minutes, followed by
termination of the reaction at 70uC, 15 min. MxA mRNA
expression levels was determined using a TaqManH Gene
Expression Assay (Applied Biosystems). Primers and probes for
MxA and the housekeeping gene GAPDH were purchased from
Applied Biosystems, cat no. Hs00895608_m1 and
Hs99999905_m1, respectively. Each qPCR was carried out in
a total volume of 20 ml containing 10 ng cDNA, 0.9 mM of each
primer and 0.25 mM probe under the following conditions: 50uC
for 2 min, 95uC for 10 min, 95uC for 15 s, 60uC for 1 min in 40
cycles. Data was analyzed using the 7500 system software for the
7500 real time PCR system and is presented as the ratio of MxA
amplificied transcripts to GAPDH amplified transcripts.
Statistical evaluations
Student’s t-test and ANOVA with Bonferronis multiple
comparison test were performed using GraphPad Prism version
5 for Window (GraphPad Software, San Diego, USA).
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